Abstract
Gene therapy is rapidly emerging as a viable clinical strategy to treat prostate cancer. New developments, such as targeted expression of therapeutic genes, and viruses that are designed to selectively replicate in prostate cancer cells have led to vectors with improved safety, even in elderly male patients. This review describes the various different viral and non-viral strategies employed to date, with a summary of current clinical trials. The main focus of the review is a discussion of the need, and the potential methods that can be used for targeted expression of the therapeutic gene specifically to prostate tumours and metastases. This includes methods of abrogating vector transduction of non-specific tissues, enhancement of transduction into prostate tumour tissue, transcriptional control of the therapeutic gene and some examples of prostate cancer-specific therapeutic genes. We also consider the future of prostate cancer gene therapy and the factors that should be taken into account when designing clinical trials, in a field that is expected to impact on clinical management of a common tumour type.
Keywords: prostate cancer, gene therapy, virus vectors, tissue specificity
Current Pharmaceutical Design
Title: Targeting Gene Therapy for Prostate Cancer
Volume: 10 Issue: 5
Author(s): N. J. Maitland, L. J. Stanbridge and V. Dussupt
Affiliation:
Keywords: prostate cancer, gene therapy, virus vectors, tissue specificity
Abstract: Gene therapy is rapidly emerging as a viable clinical strategy to treat prostate cancer. New developments, such as targeted expression of therapeutic genes, and viruses that are designed to selectively replicate in prostate cancer cells have led to vectors with improved safety, even in elderly male patients. This review describes the various different viral and non-viral strategies employed to date, with a summary of current clinical trials. The main focus of the review is a discussion of the need, and the potential methods that can be used for targeted expression of the therapeutic gene specifically to prostate tumours and metastases. This includes methods of abrogating vector transduction of non-specific tissues, enhancement of transduction into prostate tumour tissue, transcriptional control of the therapeutic gene and some examples of prostate cancer-specific therapeutic genes. We also consider the future of prostate cancer gene therapy and the factors that should be taken into account when designing clinical trials, in a field that is expected to impact on clinical management of a common tumour type.
Export Options
About this article
Cite this article as:
Maitland J. N., Stanbridge J. L. and Dussupt V., Targeting Gene Therapy for Prostate Cancer, Current Pharmaceutical Design 2004; 10 (5) . https://dx.doi.org/10.2174/1381612043453252
DOI https://dx.doi.org/10.2174/1381612043453252 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index to Volume 11
Protein & Peptide Letters Epipolythiodioxopiperazines from Fungi: Chemistry and Bioactivities
Mini-Reviews in Medicinal Chemistry Dual Role of Heat Shock Proteins (HSPs) in Anti-Tumor Immunity
Current Molecular Medicine New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Chemopreventive Effects of Conjugated Linolenic Acids (CLN) Occurring in Plant Seed Oils
Current Nutrition & Food Science Insulin-Like Growth Factor-1, a Potential Predicative Biomarker for Postoperative Delirium Among Elderly Patients with Open Abdominal Surgery
Current Pharmaceutical Design Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients
Current Pharmaceutical Biotechnology Detection of Early Cancer: Genetics or Immunology? Serum Autoantibody Profiles as Markers of Malignancy
Anti-Cancer Agents in Medicinal Chemistry Non-Photoinduced Biological Properties of Verteporfin
Current Medicinal Chemistry The Application of lncRNAs in Cancer Treatment and Diagnosis
Recent Patents on Anti-Cancer Drug Discovery Genistein Inhibits Cell Growth and Invasion Through Regulation of miR-27a in Pancreatic Cancer Cells
Current Pharmaceutical Design Prostate Cancer Immunotherapy: An Evolving Field
Current Cancer Therapy Reviews Anionic Antimicrobial Peptides from Eukaryotic Organisms
Current Protein & Peptide Science Recent Progress in Cerebrovascular Gene Therapy
Current Neurovascular Research Reprogrammed Metabolism of Cancer Cells as a Potential Therapeutic Target
Current Pharmaceutical Design Fluorescent Agonists and Antagonists for Vasopressin/Oxytocin G Protein-Coupled Receptors: Usefulness in Ligand Screening Assays and Receptor Studies
Mini-Reviews in Medicinal Chemistry Metabolomics Analysis for Biomarker Discovery: Advances and Challenges
Current Medicinal Chemistry Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism